1 / 48

2013 PARASITOLOGY WORKSHOP

2013 PARASITOLOGY WORKSHOP . LYNNE S. GARCIA, MS, FAAM, CLS, BLM Diagnostic Medical Parasitology Workshop 2013 UPDATE – PART 5 OTHER BLOOD PARASITES SPONSORED BY MEDICAL CHEMICAL CORPORATION www.med-chem.com. Babesia spp. Ixodes scapularis. BABESIA SPP. Babesia divergens : Europe

lisle
Download Presentation

2013 PARASITOLOGY WORKSHOP

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. 2013 PARASITOLOGY WORKSHOP LYNNE S. GARCIA, MS, FAAM, CLS, BLM Diagnostic Medical Parasitology Workshop 2013 UPDATE – PART 5 OTHER BLOOD PARASITES SPONSORED BY MEDICAL CHEMICAL CORPORATION www.med-chem.com

  2. Babesia spp.

  3. Ixodes scapularis BABESIA SPP. • Babesia divergens: Europe • Rare, but 42% mortality • Babesia microti: US, parts of Europe, Japan • Northeast, south to New Jersey; 5% mortality • Most cases mild; more severe in immunosuppressed • WA1, CA1, MO1 (Babesia divergens-like), states • Very serious in splenectomized patients • Related to canine pathogen, B. gibsoni • WA1, CA5: Now Babesia duncani • More pathogenic than B. microti

  4. Babesia spp.Clinical Disease • Incubation period: 1-3 weeks • Symptoms: sudden onset (B. divergens) with shock; fever, chills, confusion, jaundice • Symptoms: Mild and resolve on their own (B. microti); severe cases fulminating malaria-like symptoms (malaise, chills, myalgia, anemia, fatigue, fever, hepato- and splenomegaly); hemolytic anemia, particularly in asplenic individuals (days to months) • Severe complications: multiorgan dysfunction, renal failure, coma, death

  5. LABORATORY DIAGNOSISKEY POINTS - BABESIA • Draw blood, prepare blood films immediately • Examine 200-300 oil immersion fields on BOTH thick and thin films • Wright’s, Wright-Giemsa, Giemsa, or a rapid stain can be used (original morphology described from Giemsa stain); if WBCs look OK, then any parasites will look OK; color variation is normal • Parasites may be missed using automation • One set of negative blood films does NOT rule out Babesia; if positive, quantitate organisms present

  6. Other blood parasites: Babesia spp. ArtifactsPlasmodium falciparum

  7. LEISHMANIASIS – PARASITIC FORMS • Amastigote: round or oval, about 2-5µm, intracellular, prominent nucleus and dark staining bar-shaped structure called • Kinetoplast: includes very short flagellum • Promastigote: in the insect vector, elongate with flagellum projecting from anterior end

  8. LEISHMANIASIS – KEY FACTS~350 Million in 88 countries at risk • Cutaneous: macrophages of skin • Old World: Leishmania tropica, L. major, L. aethiopica • New World: L. mexicana, L. braziliensis • Mucocutaneous:macrophages of skin and buccal cavity or nasopharynx • Leishmania braziliensis • Visceral:macrophages of spleen, liver, bone marrow (reticuloendothelial system) • Leishmania donovani

  9. CUTANEOUS LEISHMANIASIS • Transmitted via bite of sandfly (Phlebotomus, Lutzomyia) • Multiplication of amastigotes may last months to life; usually confined to skin • Skin lesions = raised papules, ulcers on exposed parts of body • Parasite receptors to collagen may explain tropism for skin –abundant component of matrix 10

  10. CUTANEOUS LEISHMANIASIS IN U.S. MILITARY PERSONNEL 2002 - 2008 • Afghanistan, Iraq, Kuwait: >1000 cases • Cases isoenzyme analysis: L. major • Consider cutaneous leishmaniasis withskin lesions (Southwest/Central Asia) • Almost all with CL infected in Iraq • Decrease risks • Improve living conditions, heighten awareness, protective measures (permethrin- treated clothes, bed nets; exposed skin, repellent 30-35% DEET, dusk to dawn, vector control)

  11. Leishmaniasis Control Program • Program begun in 2003 (high numbers of sand flies, soldiers receiving many bites per night, 1.5% of female flies infected) • Risk assessment overall • Enhancement of use of personal protective gear • Vector and reservoir control • Education of military personnel about sand flies and leishmaniasis Coleman, RE, 2006. J Med Entomol 43:647-62.

  12. CUTANEOUS LEISHMANIASIS : CLINICAL PRESENTATION • First set of patients: median age = 29 • Deployment ~ 60 days before noting skin lesions (range of 21 to 150 days) • Median of 3 (1 to 9) skin lesions (upper and lower extremities); painless, enlarged slowly, central ulceration, often covered with eschar, surrounded by erythematous, indurated border • No patients had systemic symptoms • Microscopy of tissue, culture, isoenzyme analysis • Leishmania major

  13. CUTANEOUS LEISHMANIASIS : CLINICAL PRESENTATION

  14. CUTANEOUS LEISHMANIASIS: DIAGNOSIS • Organism isolation by smear or culture; histology • Lesion sampling: dental broach, slit scrape method, aspiration of lesion edge (multiple samples required), biopsy • Tissue sampling better than other smearing techniques; culture positive in 80% of cases • LD bodies seen in about 30% of patients; many lymphocytes/plasma cells in wet ulcerative lesions; dry lesions = granulomas / fewer cells

  15. Culture LEISHMANIASIS Specimen Collection

  16. CUTANEOUS LEISHMANIASIS : THERAPY • Since 1978: Walter Reed Army Medical Center • Pentavalent antimony: sodium stibogluconate (Pentostam, Wellcome Foundation) • Not licensed in U.S., provided by WRAMC • Treatment: 20 mg/kg body weight/day; side effects, fatigue, arthralgia, myalgia, headache, chemical pancreatitis • Microscopy of tissue, culture, isoenzyme analysis • Leishmania major

  17. MUCOCUTANEOUS LEISHMANIASIS • Transmitted via bite of sandfly (Phlebotomus, Lutzomyia) – Leishmania braziliensis • Multiplication of amastigotes: months to life; 18 mo for self-cure • Nasal, pharyngeal, buccal mucosal lesions = years after initial cutaneous lesion • ML begins with erythema, edema, inflammation, stuffiness, difficulty breathing, occasional bleeding: loss of lips, parts of nose and palate

  18. MUCOCUTANEOUS LEISHMANIASISL. mexicana Complex • Common throughout Mexico, Belize, Guatemala and southern United States (Arizona, Texas) • Forest rodents (wood rats) are important hosts • Prolonged exposure = “chicleros” live in forest collecting chewing gum latex (30% infected in first year), timber cutters, road builders, farm workers • Two culture-positive and four PCR-pos rodents Leishmania-positive. Isolates extend geographic and ecologic range of enzootic leishmaniasis in the United States and represent a new host record. Now in Tucson, Arizona.

  19. MUCOCUTANEOUS LEISHMANIASIS

  20. VISCERAL LEISHMANIASIS(Kala Azar) • Amastigotes in macrophages disseminate to liver, spleen, and bone marrow; hepatomegaly and splenomegaly • Protective Th-1 responses are reduced or absent • Hypergammaglobulinemia present but does not clear the infection

  21. VISCERAL LEISHMANIASIS(Kala Azar) • Transmitted via bite of sandfly (Phlebotomus, Lutzomyia) – Leishmania donovani • Patients who have recovered may develop skin lesions – post kala-azar dermal leishmaniasis • Cell mediated responses absent = develop after successful treatment • VL begins with fever (double peaks) –hepatosplenomegaly; weight loss, nose bleeds, diarrhea, cough; elevated gammaglobulins

  22. VISCERAL LEISHMANIASIS

  23. LEISHMANIASISCure – Yes or No? • Currently, no reliable way to assess cure • Most researchers think sterile cure is unlikely and/or uncommon • Evidence: • Reactivation years later (immunosuppressed or “traumatized” persons & animals) • Demonstration of organisms years after exposure, self-healing, or treatment • Persistence of immunologic markers • Extrapolation of information about other intracellular pathogens

  24. OTHER BLOOD PARASITES(Trypanosomes) • African Trypanosomiasis, T. brucei gambiense* (West), T. brucei rhodesiense (East) Tsetse fly • African Sleeping Sickness (chronic*, CNS disease) • Acute or chronic disease, blood, buffy coat, CSF • American Trypanosomiasis, Trypanosoma cruzi • Triatomid bug (feces), blood, shared needles, congenital, organ transplants • Myocarditis, GI tract, acute or chronic disease • Blood, buffy coat, culture, xenodiagnosis • Trypanosoma rangeli (like T. cruzi) • Nonpathogen, but overlaps geographic range

  25. TRYPANOSOMIASIS, AFRICAN • Caused by Trypanosoma brucei gambiense (West) and T. b. rhodesiense (East) • Transmitted by bite of tsetse fly (Glossina spp.) • T. b. gambiense in West, Central Africa by rivers and streams; animal reservoirs insignificant • T. b. rhodesiense in East, Central Africa in the savanna; wild game major reservoir hosts • After initial development in skin, trypomastigotes found in blood, lymph notes, and CSF

  26. 27

  27. TRYPANOSOMIASIS, AFRICAN – CLINICAL DISEASE • Primary lesion may develop at bite site - chancre • Fever earliest sign of generalized infection • T. b. gambiense - after initial development in skin, trypomastigotes in blood, – fever delayed months to years; chronic – onset of CNS slow – death often > year after infection • T. b. rhodesiense – fever begins days to weeks; rapidly progressive illness – may die of myocarditis before CNS is invaded; patients often die of infection, including pneumonia

  28. TRYPANOSOMIASIS, AFRICAN – LABORATORY DIAGNOSIS • Trypomastigotes in early cases with no evidence of CNS disease • If lymphadenopathy, lymph node aspiration; if CNS involved, centrifuged CSF; detection of IgM in CSF; very high gamma globulins – variant surface glycoproteins (VSG); antigenic variation • T. b. gambiense – may be more difficult to diagnose; fewer trypomastigotes seen • T. b. rhodesiense – higher parasitemia seen

  29. African Trypanosomiasis

  30. Trypomastigote Culture: African Trypanosomes

  31. SUMMARY • T. b. gambiense and T. b. rhodesiensetrypomastigotes are found in the blood • West African disease more chronic – progresses to actual sleeping sickness with invasion of the CNS • East African disease more acute – often leads to death within a year prior to typical CNS invasion • T. b. gambiense and T. b. rhodesiense (animal reservoirs) transmitted by the tsetse fly.

  32. AMERICAN TRYPANOSOMIASIS(No longer South American) • Chagas’ Disease – Trypanosoma cruzi • Transmission – infective organisms in feces of blood-sucking triatomid bugs (kissing bugs, reduviid bugs); oral infections new problem • Bug’s feces contact site of bug bite or mucus membranes; transfusions, congenital infections • Mexico, Central, South, and North America (Texas, California); rural areas; dogs, cats, opossums, rodents, armadillos important reservoir hosts

  33. Spread of Triatomid Bugs

  34. CONFIRMED BLOOD DONATIONS: CHAGAS’ DISEASE Triatomid bugs: range

  35. TRYPANOSOMIASIS, AMERICAN – CLINICAL DISEASE • Initial infection often asymptomatic – evidence years later as chronic form of disease; acute disease more common in children • Unilateral periorbital edema (Romaña’s sign) • Local lesion followed by fever, lymphadenopathy, hepatosplenomegaly, myocarditis, meningoencephalitis • Chronic disease = cardiomyopathy, congestive heart failure or arrhythmias; dilation of esophagus or colon; “MEGASYNDROME”

  36. TRYPANOSOMIASIS, AMERICAN – LABORATORY DIAGNOSIS • Trypomastigotes in blood in acute cases; very few in chronic cases • Lab workers use blood-borne pathogen precautions; tryps are infective • Blood concentrations can be performed. • Immunoassays for antigen detection highly sensitive and specific. • U.S. : 23 vector-borne; 5 organ cases; 300,000 active infections; unrecognized or suspected

  37. SUMMARY • Trypanosoma cruzitrypomastigotes are found in the blood; amastigotes in skeletal muscle (cardiac, GI tract) • Trypanosoma cruzi transmitted by organisms within triatomid bug feces • Acute disease more common in children • Disease progression leads to cardiomyopathy, megasyndrome and death

  38. Leishmania, Trypanosoma

  39. DISEASES ENDEMIC IN THIRD WORLD & BLOOD SUPPLY: Malaria • Plasmodium falciparum, P. vivax, P. ovale, P. malariae (chloroquine, primaquine) • Female mosquito, transfusion, congenital transplantation, shared needles • Severe infections with P. falciparum • Asymptomatic to death • Approximately 3 million deaths, children • P. knowlesi: risk not well defined

  40. DISEASES ENDEMIC IN BLOOD SUPPLY: Malaria Diagnosis • Diagnosis: microscopy very difficult • Binax (approval April ’07) • Rapid methods as sensitive as expert microscopist • APPROACH TO STAT TESTING • Perform rapid test on STAT basis • If negative, read thick/thin films AM • If positive, read thick/thin films to confirm species

  41. PARASITES IN THE BLOOD SUPPLY Babesia spp. • Europe: B. divergens; U.S.: B. microti • Ixodid tick, transfusion, congenital, shared needles, transplantation • B. divergens = more severe disease • B. microti, may be asymptomatic, self-limited, compromised = severe anemia, renal failure, death • Not easy to control blood transmission • Diagnosis: microscopy confusing, mimics malaria • East, West coasts, different species

  42. PARASITES IN THE BLOOD SUPPLY: Trypanosoma cruzi • Latin America, Mexico, U. S. - 16-18 million • Triatomid bug, transfusion, congenital, needles, transplantation; compromised = reactivation • Acute (pediatric); chronic (10-30% cardiac) • 40% with cardiomyopathy, aneurysms • HIV, reactivated disease CNS • Diagnosis: blood/tissue microscopy; tryps in blood, amastigotes in tissues; specific IgG serologies • In U.S. and Canada, 50,000-100,000 infected • Red Cross now screening donors (U.S. – 1/19/07)

  43. THANKS – QUESTIONS?

More Related